# LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

> **NCT01257477** · — · COMPLETED · sponsor: **Prometheus Laboratories** · enrollment: 400 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01257477
- **Lead sponsor:** Prometheus Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2013-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257477, "LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01257477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*